Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A phase 2 trial of PF-07248144, Fulvestrant, Letrozole in prostate cancer and non-small-cell lung cancer, run by Pfizer, now recruiting.
Overview
Study of PF-07248144 in Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT04606446 by Pfizer, with 320 participants planned, started 2020-11-16 and due to reach its primary completion in 2029-07-13. Interventions recorded: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060. Conditions listed: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Shares Atirmociclib, Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
- TrialPF-07104091 as a Single Agent and in Combination Therapy
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
- TrialA Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Shares Atirmociclib, Vepdegestrant, Pfizer (incl. Seagen).
- TrialA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares Atirmociclib, Fulvestrant, Pfizer (incl. Seagen).
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Vepdegestrant, Palbociclib, Pfizer (incl. Seagen).
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares PF-07248144, Pfizer (incl. Seagen).
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Atirmociclib, Palbociclib, Pfizer (incl. Seagen).
- TrialStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.